CytoReason Ltd. announced that it will raise $20 million in a round of funding on September 20, 2022. The transaction will include participation from new investor, Pfizer Inc. The company will issue equity in the transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.41 USD | +1.59% |
|
-0.90% | -4.79% |
Jun. 18 | Global markets live: Shell, UBS, Boeing, Berkshire Hathaway, Exxon... | ![]() |
Jun. 18 | Sector Update: Health Care Stocks Flat to Lower Premarket Tuesday | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.79% | 155B | |
+52.93% | 803B | |
+41.34% | 631B | |
-7.08% | 351B | |
+17.40% | 324B | |
+10.58% | 303B | |
+16.13% | 243B | |
+2.04% | 228B | |
+10.30% | 217B | |
+6.24% | 164B |
- Stock Market
- Equities
- PFE Stock
- News Pfizer, Inc.
- CytoReason Ltd. announced that it expects to receive $20 million in funding from Pfizer Inc.